Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Mar 06, 2024 (filed on Mar 08, 2024)Insider Name:Sandercock ColinOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:175,000Price:--
-
Mar 06, 2024 (filed on Mar 08, 2024)Insider Name:Millar Kerri-AnnOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:250,000Price:--
-
Mar 06, 2024 (filed on Mar 08, 2024)Insider Name:Suri AnishOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:300,000Price:--
-
Mar 06, 2024 (filed on Mar 08, 2024)Insider Name:Passeri Daniel ROwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:400,000Price:--
-
Mar 06, 2024 (filed on Mar 08, 2024)Insider Name:Levisetti MatteoOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:260,000Price:--
-
Feb 20, 2024 (filed on Feb 22, 2024)Insider Name:Levisetti MatteoOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:25,000Price:--
-
Jan 02, 2024 (filed on Jan 04, 2024)Insider Name:Garzone PamelaOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:24,400Price:--
-
Jan 02, 2024 (filed on Jan 04, 2024)Insider Name:Kiener Peter AOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:24,400Price:--
-
Jan 02, 2024 (filed on Jan 04, 2024)Insider Name:Driscoll Frederick WOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:24,400Price:--
-
Jan 02, 2024 (filed on Jan 04, 2024)Insider Name:Verheyen PatrickOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:24,400Price:--
Filings by filing date
-
Mar 06, 2024 (filed on Mar 08, 2024)Insider Name:Sandercock ColinOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:175,000Price:--
-
Mar 06, 2024 (filed on Mar 08, 2024)Insider Name:Millar Kerri-AnnOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:250,000Price:--
-
Mar 06, 2024 (filed on Mar 08, 2024)Insider Name:Suri AnishOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:300,000Price:--
-
Mar 06, 2024 (filed on Mar 08, 2024)Insider Name:Passeri Daniel ROwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:400,000Price:--
-
Mar 06, 2024 (filed on Mar 08, 2024)Insider Name:Levisetti MatteoOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:260,000Price:--
-
Feb 20, 2024 (filed on Feb 22, 2024)Insider Name:Levisetti MatteoOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:25,000Price:--
-
Jan 02, 2024 (filed on Jan 04, 2024)Insider Name:Garzone PamelaOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:24,400Price:--
-
Jan 02, 2024 (filed on Jan 04, 2024)Insider Name:Kiener Peter AOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:24,400Price:--
-
Jan 02, 2024 (filed on Jan 04, 2024)Insider Name:Driscoll Frederick WOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:24,400Price:--
-
Jan 02, 2024 (filed on Jan 04, 2024)Insider Name:Verheyen PatrickOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:24,400Price:--
News
Biz Brief
Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 40 Guest Street BOSTON MA 02135 |
Tel: | 1-617-9492602 |
Website: | https://www.cuebiopharma.com |
IR: | See website |
Key People | ||
Anish Suri President, Chief Scientific Officer | Daniel R. Passeri Chief Executive Officer, Director | Kerri-Ann Millar Chief Financial Officer |
Colin G. Sandercock Senior Vice President, General Counsel, Secretary | Matteo Levisetti Chief Medical Officer | Patricia Nasshorn Chief Business Officer |
Business Overview |
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells. The Company's platform, Immuno-STAT (Selective Targeting and Alteration of T cells) and biologics are designed to harness the curative potential of the body's intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation. Its two oncology drug product candidates, CUE-101 and CUE-102, are exemplary programs from the interleukin 2 (IL-2) based CUE-100 series, and are representative of the HLA-A02 allele, which is prevalent in the United States and western European territories. CUE-101 HLA-A02 is engineered for the treatment of human papillomavirus positive, head and neck squamous cell carcinoma (HNSCC). CUE-102 HLA-A02, targeting Wilms' Tumor 1 protein, an oncofetal antigen known to be over-expressed in more than 20 different cancers. |
Financial Overview |
For the fiscal year ended 31 December 2023, Cue Biopharma Inc revenues increased from $1.2M to $5.5M. Net loss decreased 4% to $50.7M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Research and development - Balancing va decrease of 22% to $23.2M (expense), General and administrative - Balancing decrease of 34% to $7M (expense). |
Employees: | 53 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $60.83M as of Dec 31, 2023 |
Annual revenue (TTM): | $5.49M as of Dec 31, 2023 |
EBITDA (TTM): | -$51.44M as of Dec 31, 2023 |
Net annual income (TTM): | -$50.73M as of Dec 31, 2023 |
Free cash flow (TTM): | -$39.96M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 48,643,316 as of Mar 25, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |